FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease

The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically for the management of agitation associated with Alzheimer’s disease. This landmark decision marks a significant advancement in addressing one of the most challenging and distressing symptoms of Alzheimer’s, offering a new therapeutic pathway that distinguishes itself from existing options, particularly by not being classified as an antipsychotic medication. The approval of Auvelity, developed by Axsome Therapeutics, provides a long-awaited and much-needed treatment for millions of patients, their families, and caregivers who have historically faced limited and often high-risk interventions for Alzheimer’s-related agitation.

The Pervasive Challenge of Agitation in Alzheimer’s

Alzheimer’s disease, a progressive neurodegenerative disorder, is characterized by a gradual decline in cognitive function, including memory, thinking, and reasoning skills. Beyond cognitive impairment, a significant proportion of individuals with Alzheimer’s experience a range of behavioral and psychological symptoms of dementia (BPSD), with agitation being one of the most common and disruptive. Agitation in Alzheimer’s can manifest in various ways, from restless pacing and repetitive vocalizations to aggressive behaviors such as verbal outbursts or physical lashing out. Studies indicate that agitation affects approximately three-quarters of people living with Alzheimer’s at some point during their disease progression, posing immense challenges for both patients and their caregivers.

The impact of agitation extends far beyond the immediate distress it causes. As highlighted by Jeffrey Cummings, MD, a professor at the Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, agitation in Alzheimer’s is "associated with accelerated cognitive decline, placement in assisted living and long-term care facilities, and increased mortality risk." For caregivers, managing agitation is often cited as one of the most stressful and burdensome aspects of caregiving, leading to increased caregiver burnout, depression, and a reduced quality of life. The economic burden is also substantial, with agitation contributing to higher healthcare utilization, including emergency room visits and hospitalizations. Until now, the treatment landscape for Alzheimer’s-related agitation has been critically underserved, largely relying on off-label use of antipsychotic medications, which carry significant safety concerns.

A New Paradigm: Differentiating Auvelity from Antipsychotics

For decades, clinicians have resorted to prescribing antipsychotics off-label to manage severe agitation in Alzheimer’s patients. While these medications can sometimes mitigate symptoms, their use is fraught with risks. The FDA has issued "black box" warnings for antipsychotics when used in elderly patients with dementia-related psychosis, noting an increased risk of death, as well as an elevated risk of stroke and other adverse cardiovascular events. This stark reality has underscored a profound unmet medical need for safer and more targeted treatments.

Auvelity emerges as a groundbreaking alternative because it is the only FDA-approved treatment for Alzheimer’s-related agitation that is not classified as an antipsychotic. This distinction is paramount. Joanne Pike, president and CEO of the Alzheimer’s Association, emphasized this point in a press release, stating, "For too long, people living with Alzheimer’s disease agitation and their families have had limited options, and the options that existed came with significant risks. This approval gives patients, caregivers and clinicians an important new tool — one that works through a different mechanism than antipsychotic medications and that can help address a symptom that profoundly affects quality of life for people living with Alzheimer’s and those who care for them."

The mechanism of action for Auvelity, a combination of dextromethorphan and bupropion, is distinct from traditional antipsychotics. It is designed to ease agitation by modulating the activity of two specific brain cell receptors: the N-methyl-D-aspartate (NMDA) receptor and the sigma-1 receptor. Dextromethorphan, an NMDA receptor antagonist and sigma-1 receptor agonist, is the active therapeutic component. Bupropion serves to increase the bioavailability of dextromethorphan by inhibiting its metabolism, allowing it to reach therapeutic concentrations in the brain. This unique neuromodulatory approach offers a targeted intervention for the complex neurobiological underpinnings of agitation without the broad and often severe side effects associated with antipsychotics. It is noteworthy that Auvelity was already FDA-approved to treat adults with major depressive disorder, indicating its established safety profile for certain neurological conditions.

Clinical Evidence Paving the Way for Approval

Axsome Therapeutics’ application for FDA approval of Auvelity for Alzheimer’s-related agitation was supported by a robust body of evidence derived from a comprehensive battery of clinical trials. These included four Phase 3 studies: ACCORD (NCT04797715), ACCORD-2 (NCT04947553), ADVANCE-1 (NCT03226522), and ADVANCE-2 (NCT05557409), alongside an extension study (NCT06736509) designed to monitor long-term outcomes and safety.

The ACCORD and ACCORD-2 studies were particularly instrumental in demonstrating Auvelity’s ability to prevent the recurrence of agitation. In these studies, participants initially received Auvelity. Those who experienced a substantial reduction in agitation, as assessed by the Cohen-Mansfield Agitation Inventory (CMAI), a widely recognized standardized test for measuring agitation, were then randomized to either continue active therapy or switch to a placebo. The results from both studies consistently showed that patients who transitioned to a placebo were significantly more likely to experience a relapse of agitation compared to those who maintained treatment with Auvelity. George Grossberg, MD, a professor at the Saint Louis University School of Medicine, highlighted this critical finding, stating, "Auvelity is the only FDA-approved product to result in a statistically significantly longer time to relapse of agitation symptoms, compared to placebo, in a long-term study." This relapse prevention capability offers substantial hope for maintaining stability in patients’ conditions over time.

The ADVANCE-1 and ADVANCE-2 studies directly compared Auvelity against a placebo in patients with Alzheimer’s-related agitation. In the smaller ADVANCE-1 study, Auvelity demonstrated a statistically significant superiority over placebo in reducing agitation, as measured by CMAI scores. While the larger ADVANCE-2 study also showed a trend toward reductions in agitation with Auvelity compared to placebo, the difference did not achieve statistical significance. This outcome, though not statistically significant in one trial, must be considered within the totality of the clinical evidence, which collectively points to a beneficial effect. The overall efficacy demonstrated across the program, particularly the relapse prevention data, provided the necessary clinical confidence for the FDA’s decision.

Safety and Tolerability Profile

A crucial aspect of any new medication, especially for a vulnerable population like elderly Alzheimer’s patients, is its safety and tolerability profile. The clinical trials for Auvelity indicated a compelling safety and tolerability profile. Rates of discontinuation due to adverse events were low and comparable to those observed in the placebo groups, suggesting that the medication is generally well-tolerated. According to the newly approved therapy’s prescribing information, the most common side effects reported in Alzheimer’s patients were dyspepsia (indigestion) and dizziness.

As Auvelity contains bupropion, an antidepressant component, its prescribing information includes a black box warning—the FDA’s most stringent safety warning—regarding an increased risk of suicidal thoughts and behaviors in young people, consistent with warnings for many antidepressant medications. While this warning is standard for such compounds, it underscores the importance of careful patient selection and monitoring, particularly when considering the broader patient population for which Auvelity is approved (including major depressive disorder). However, for the specific indication of Alzheimer’s-related agitation in an elderly population, the overall safety data, especially the low discontinuation rates, was a reassuring factor in its approval.

Stakeholder Reactions and Broader Implications

The approval of Auvelity has been met with widespread enthusiasm from the medical community, patient advocacy groups, and the pharmaceutical industry. Herriot Tabuteau, MD, CEO of Axsome Therapeutics, articulated the company’s pride: "The approval of our first-in-class medication for agitation associated with Alzheimer’s disease marks an important milestone for the millions of patients living with Alzheimer’s disease, their families, and their caregivers. We are very pleased to deliver to clinicians and patients a new, effective, FDA-approved treatment option, with a distinct mechanism of action, for this debilitating and critically underserved condition."

Frank Longo, MD, PhD, a professor of neurology at Stanford University and co-founder of Pharmatrophix, echoed this sentiment, noting that the FDA’s approval "highlights the advances being made in addressing the day-to-day realities of the disease." He added that "for patients and caregivers, any progress in Alzheimer’s treatment is meaningful. This milestone… reflects the growing momentum in innovative treatments for neurodegenerative diseases and further underscores the continued need for disease-modifying therapies."

The introduction of Auvelity is expected to significantly impact the landscape of Alzheimer’s care. It offers clinicians a non-antipsychotic option, potentially reducing the reliance on medications with known severe side effects. This shift could lead to improved quality of life for patients, reducing distress and potentially slowing the progression to institutionalization. For caregivers, the availability of an effective treatment for agitation could alleviate immense stress and improve their own well-being.

Axsome Therapeutics has also committed to supporting patient access to Auvelity. The company announced that upon commercial launch, it will introduce the "Auvelity OnMySide" patient support program. This program is designed to provide comprehensive resources, including financial aid and insurance assistance, for eligible patients, ensuring that this new treatment option is accessible to those who need it. The commercial launch is anticipated to commence in early 2025.

Looking Ahead: A Step Towards Holistic Alzheimer’s Care

The approval of Auvelity represents a pivotal moment in Alzheimer’s research and treatment. While the ultimate goal remains the development of disease-modifying therapies that can halt or reverse the progression of Alzheimer’s, addressing the challenging symptomatic manifestations like agitation is crucial for improving the daily lives of affected individuals and their support networks. This approval reinforces the FDA’s commitment to facilitating the development of treatments for neurodegenerative diseases and underscores the importance of targeting specific, burdensome symptoms.

The success of Auvelity may also encourage further research into non-antipsychotic approaches for other behavioral and psychological symptoms of dementia, potentially opening new avenues for drug development in a field that has long struggled with limited options. As the global population ages, the prevalence of Alzheimer’s disease and related dementias is projected to rise dramatically, making innovations like Auvelity increasingly vital. This new treatment offers not just a pharmaceutical option, but a renewed sense of hope for better, more humane care for those living with the profound challenges of Alzheimer’s disease.